PD-1 plus chemotherapy before surgery for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies whether giving a PD-1 antibody together with standard chemotherapy before surgery can improve outcomes for people with stage IIIB–IIIC non-small cell lung cancer. It aims to shrink or control the cancer and make treatment before surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must agree to sign an informed consent form
- You are 18 years or older
- Your lung cancer is non-small cell lung cancer (NSCLC), stage IIIB or IIIC, confirmed by scans and a biopsy
- Your daily functioning is good (ECOG score 0 or 1)
- Your cancer has no spread to distant organs (no systematic metastasis), and you have at least one measurable tumor spot
- You must have enough organ health (liver, kidneys, blood counts, etc.) and be able to tolerate surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests whether giving chemotherapy plus immunotherapy before surgery helps people with a specific type of advanced lung cancer. It aims to see if this approach can shrink tumors and make surgery more effective.
This Phase 2 study tests whether adding a PD-L1 antibody to chemotherapy helps people with newly diagnosed limited-stage small-cell lung cancer live longer and control the cancer better. It may benefit patients who have not had any prior cancer treatment for SCLC and can meet health and lab requirements.
This Phase 2 study looks at how safe and effective serplulimab (an immune medicine) combined with chemotherapy is when used as a “conversion” plan—first shrinking lung cancer, then trying to remove the main tumor with surgery. It may help some people who are not initially good candidates for surgery or focused radiation to become eligible after treatment.
Hear when a new Locally Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.